Patients with Alzheimer's disease (AD) present with both extracellular amyloid-β (Aβ)
plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years …

The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment
can revert or arrest progression of this disease. AD pathology is characterized by the …

Alzheimer's disease (AD) causes unrelenting, progressive cognitive impairments, but its
course is heterogeneous, with a broad range of rates of cognitive decline. The spread of tau …

BACKGROUND The microtubule-associated protein tau has been implicated in the
pathogenesis of Alzheimer's disease and a range of other neurodegenerative disorders …

The links between β-amyloid (Aβ) and tau in Alzheimer's disease are unclear. Cognitively
unimpaired persons with signs of Aβ pathology had increased cerebrospinal fluid (CSF) …

Tau is the major constituent of neurofibrillary tangles in Alzheimer's disease (AD), but the
mechanism underlying tau-associated neural damage remains unclear. Here, we show that …

Alzheimer's disease (AD) is a prevalently found tauopathy characterized by memory loss
and cognitive insufficiency. AD is an age-related neurodegenerative disease with two major …

Tau aggregates contribute to neurodegenerative diseases, including frontotemporal
dementia and Alzheimer's disease (AD). Although RNA promotes tau aggregation in vitro …

Neurodegenerative diseases of the central nervous system progressively rob patients of
their memory, motor function, and ability to perform daily tasks. Advances in genetics and …

Alzheimer's disease (AD) is pathologically defined by extracellular accumulation of amyloid-
β (Aβ) peptides generated by the cleavage of amyloid precursor protein (APP), strings of …